Leaderboards/Urinary and Genital Oncology Studies

Urinary and Genital Oncology Studies

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Qingfei Meng
Jilin University
2
Kenneth Gouin
Joint Center for Structural Genomics
3
Yuki Arita
Memorial Sloan Kettering Cancer Center
4
Florus C. de Jong
Erasmus MC Cancer Institute
5
Jeroen van Dorp
The Netherlands Cancer Institute
6
Sarah Lidagoster
Mount Sinai Hospital
7
Alberto Contreras‐Sanz
University of British Columbia
8
Jianpeng Li
Dongguan People’s Hospital
9
Wolfgang Beckabir
University of North Carolina at Chapel Hill
10
Emily Gill
Southmead Hospital

Papers

1
Lactylation stabilizes DCBLD1 activating the pentose phosphate pathway to promote cervical cancer progression
Journal of Experimental & Clinical Cancer Research|2024
108 cit.
2
Human papillomavirus-16 E6 activates the pentose phosphate pathway to promote cervical cancer cell proliferation by inhibiting G6PD lactylation
Redox Biology|2024
72 cit.
3
BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer
Current Oncology|2024
48 cit.
4
Publication in Asian journal of urology (2025) [25 citations, W4407818742]
Asian journal of urology|2025
25 cit.
5
Publication in Insights into Imaging (2025) [24 citations, W4406001403]
Insights into Imaging|2025
24 cit.
6
PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG
World Journal of Urology|2025
8 cit.
7
Publication in European Urology Open Science (2024) [5 citations, W4392671032]
European Urology Open Science|2024
5 cit.
8
Publication in European Urology Open Science (2024) [W4399797599]
European Urology Open Science|2024
0 cit.
9
Publication in Cancer Research (2025) [W4409625741]
Cancer Research|2025
0 cit.
10
Publication in Regular and Young Investigator Award Abstracts (2025) [W4415900105]
Regular and Young Investigator Award Abstracts|2025
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Alyse Johnson-Chilla
National Comprehensive Cancer Network
2
Julia A. Beaver
Center for Drug Evaluation and Research
3
Lisa A. Gurski
National Comprehensive Cancer Network
4
Stephanie C. Hodges
University of Virginia
5
Christopher Hoimes
Duke Medical Center
6
Max Kates
Duke Medical Center
7
Jean Hoffman‐Censits
Sidney Kimmel Comprehensive Cancer Center
8
Lynn Hoang
Vancouver Coastal Health
9
Kent W. Mouw
Massachusetts General Hospital
10
Kara A. Lombardo
Johns Hopkins University

Papers

1
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2022
819 cit.
2
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
Journal of the National Comprehensive Cancer Network|2022
302 cit.
3
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
Journal of Clinical Oncology|2022
267 cit.
4
Bladder Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network|2024
236 cit.
5
NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network|2024
215 cit.
6
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors
Clinical Cancer Research|2022
171 cit.
7
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Journal of the National Comprehensive Cancer Network|2024
166 cit.
8
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021
JAMA Oncology|2022
80 cit.
9
Classification of Vulvar Squamous Cell Carcinoma and Precursor Lesions by p16 and p53 Immunohistochemistry: Considerations, Caveats, and an Algorithmic Approach
Modern Pathology|2023
56 cit.
10
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)
European Urology Focus|2023
48 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Thomas Powles
Queen Mary University of London
2
Jonathan I. Epstein
Johns Hopkins University
3
Robert H. Young
George Washington University Hospital
4
Liang Cheng
Brown University
5
Donald G. Skinner
Stellenbosch University
6
Mahul B. Amin
Ontario Institute for Cancer Research
7
Alberto G. Ayala
The University of Texas MD Anderson Cancer Center
8
David J. McConkey
Johns Hopkins University
9
Robert E. Scully
Ollscoil na Gaillimhe – University of Galway
10
Andrew W. Bruce
Amgen (Australia)

Papers

1
The Eighth Edition <scp>AJCC</scp> Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging
CA A Cancer Journal for Clinicians|2017
6.5k cit.
2
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Nature|2018
5.5k cit.
3
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
Journal of Clinical Oncology|2001
3.5k cit.
4
Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors
The Journal of Urology|1976
1.8k cit.
5
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
Cancer Cell|2014
1.7k cit.
6
Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors
The Journal of Urology|2016
1.5k cit.
7
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
European Urology|2015
1.4k cit.
8
Diagnosis and management of renal cell carcinomaA clinical and pathologic study of 309 cases
Cancer|1971
991 cit.
9
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
JAMA Oncology|2017
846 cit.
10
Correlation of pathologic findings with progression after radical retropubic prostatectomy
Cancer|1993
753 cit.

Reagents for Urinary and Genital Oncology Studies

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling Technology

Tri-Methyl-Ezh2 (Lys509) (F1D1Q) Rabbit Monoclonal Antibody

#9994$176,437
View Evidence →
Cell Signaling TechnologyEvidence 64

TGF-beta Receptor III (D11G10) Rabbit Monoclonal Antibody

#5544$161,351
View Evidence →
Agilent/DakoEvidence 62

CD20cy

#M0755
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 65

Phospho-Rb (Ser807/811) (D20B12) Rabbit Monoclonal Antibody (Pacific Blue™ Conjugate)

#75864$493
View Evidence →
Cell Signaling TechnologyEvidence 66

SH3BP4 (D3D9I) Rabbit Monoclonal Antibody

#55935$161,351
View Evidence →
Agilent/Dako

Collagen IV

#M0785
View Evidence →